Job Opportunity

[Anonymous]

Got a hit regarding an opening in my territory. I couldn't believe you guys were still around let alone hiring. I've got only 2 yrs of pharma experience but have solid numbers. Looking to make a change and would like the chance to acquire injectable and buy and bill experience. I need to get back to the recruiter by next week. Any feedback on the status of your company would help.

 

[Anonymous]

Got a hit regarding an opening in my territory. I couldn't believe you guys were still around let alone hiring. I've got only 2 yrs of pharma experience but have solid numbers. Looking to make a change and would like the chance to acquire injectable and buy and bill experience. I need to get back to the recruiter by next week. Any feedback on the status of your company would help.

If you were smart, I'd stay away from this cesspool!! The chapter 11 bankruptcy has still not been resolved, the management of this company is terrible (all the way up the chain of command) and the products suck (terrible managed care coverage, doctors still p!$$ed about Makena's price and the availability of compounded 17P). I would only do it for a short time just to get the experience. Oh yeah, don't expect to get too much of a raise or bonus either. (remember, the company is in chapter 11 bankruptcy). One other thing, be prepared to use your own credit card to pay for your lunches (no company card).

 

[Anonymous]

If you were smart, I'd stay away from this cesspool!! The chapter 11 bankruptcy has still not been resolved, the management of this company is terrible (all the way up the chain of command) and the products suck (terrible managed care coverage, doctors still p!$$ed about Makena's price and the availability of compounded 17P). I would only do it for a short time just to get the experience. Oh yeah, don't expect to get too much of a raise or bonus either. (remember, the company is in chapter 11 bankruptcy). One other thing, be prepared to use your own credit card to pay for your lunches (no company card).

Thanks so much for the feedback. I think I'd like to try it for a short while and then move on. The injectable and buy&bill experience could lead to a better biotech position in the future. The recruiter quoted me 65K base and another 20K in bonus. Not bad. As far as spending my own credit card...I have no problem with that at all. I actually prefer to use my credit card because I can rack up on all the points and cash in for flights, electronics, hotel stays, etc. I keep thinking you guys are going to sink and then you don't. Seems like you guys have survived the worst part of the storm.

 

[Anonymous]

You'll get some really good experience at being thrown out of OB/Gyns offices, since they still are not too happy with KV/TherRx over the Makena pricing circus. Moreover, you'll get to experience a management team that has the distinction of wining surveys like "worst CEO" and "worst managed pharma" and "company I'd least want to work for". Frankly, if it's good management experience you are looking for, I stay as far away from this company as possible.

 

[Anonymous]

You must be stupid or worked for Greg, Mike or get a clue or both. We are all looking to get bout and the leaders here are joke. HR will feed you this bs and when you accept reality hits. Take this job if you want to but to get experience that is funny. Take bit double dip like the rest if us.

BTW ask about the success of the makena care connection

Enough said

 

[Anonymous]

ah, yes... the Makena Care Connection. TherRx's brainchild to shift from screwing the patient/doctor to screwing the 3rd party payer (insurance company or government) for the outrageous price of Makena. In the end, TherRx got screwed since the 3rd party refused to pay for Makena over the compounded versions.

 

[Anonymous]

What kind of compnay cars do you get? I am thinking about join this company as it looks pretty good. How is managers and how long training?

 

[Anonymous]

You must be stupid or worked for Greg, Mike or get a clue or both. We are all looking to get bout and the leaders here are joke. HR will feed you this bs and when you accept reality hits. Take this job if you want to but to get experience that is funny. Take bit double dip like the rest if us.

BTW ask about the success of the makena care connection

Enough said

Well he certainly can't be any stupider than you. Afterall, you currently work for the company instead of bailing a long time ago. Which means not only are you stupid, you obviously suck too.

 

[Anonymous]

What kind of compnay cars do you get? I am thinking about join this company as it looks pretty good. How is managers and how long training?

What do they do, put hallucinogens in your coffee during an initial interview? How can this company look "pretty good" when their major product, Makena, is only reaching about 15% of the potential patients due to the unreasonable pricing of the product and the competition with compounded versions of the drug. Additionally, their newly re-introduced Gynazole-1 is not gaining favor with OB/Gyns, trending to achieve only about $1 million in annual revenue since remarketing began in January.
The company is a poorly managed circus. Have you noted that Divis, the CEO, has been awarded the dubious distinction of being voted the worst CEO two years in a row?

 

[Anonymous]

you are dumber then a box of rocks to work here.

What about the forced Presidents club dinner; wasn't that a joke. How about the "we will be premier" woman's health care speech. What's with all the cheering during the meeting? Did I miss the Cool Aid station? How about blaming us for the poor launch of GY-1. Here a thought, Marketing, Managed Care?

Lets only hope we have new leadership soon.

BTW, I guess we already screwed the launch again.

 

[Anonymous]

you are dumber then a box of rocks to work here.

What about the forced Presidents club dinner; wasn't that a joke. How about the "we will be premier" woman's health care speech. What's with all the cheering during the meeting? Did I miss the Cool Aid station? How about blaming us for the poor launch of GY-1. Here a thought, Marketing, Managed Care?

Lets only hope we have new leadership soon.

BTW, I guess we already screwed the launch again.

Yep, KV certainly has a knack in messing up product launches. Gynazole-1 launch needed consideration of the fact that the 3rd party payers gained significant influence in the time that G-1 off the market. They simply won't pay for, or have high co-pays, for G-1 since there are much cheaper effective alternatives in both the Rx and OTC marketplace that are one-dose-to-cure. Pricing of G-1 needed to be in concert with the price of the OTC and other Rx single dose products... and G-1 is not. The goofuses at KV even think that creating a patient voucher to subsidize the co-pay will work. It won't ... the 3rd party will not stand for the cost of G-1, and KV could not absorb the voucher cost long term anyway.

For G-1 to have any possibility of success (success being in excess of $10-15 million in annual revenue generated, the average wholesale price of the product needs to be somewhere around $14 to $17 ($20 - $28 cost of the Rx for the patient), at this level prescribed G-1 becomes an option for the patient irregardless of what the 3rd party payer does or pays for.

 

[Anonymous]

Yep, KV certainly has a knack in messing up product launches. Gynazole-1 launch needed consideration of the fact that the 3rd party payers gained significant influence in the time that G-1 off the market. They simply won't pay for, or have high co-pays, for G-1 since there are much cheaper effective alternatives in both the Rx and OTC marketplace that are one-dose-to-cure. Pricing of G-1 needed to be in concert with the price of the OTC and other Rx single dose products... and G-1 is not. The goofuses at KV even think that creating a patient voucher to subsidize the co-pay will work. It won't ... the 3rd party will not stand for the cost of G-1, and KV could not absorb the voucher cost long term anyway.

For G-1 to have any possibility of success (success being in excess of $10-15 million in annual revenue generated, the average wholesale price of the product needs to be somewhere around $14 to $17 ($20 - $28 cost of the Rx for the patient), at this level prescribed G-1 becomes an option for the patient irregardless of what the 3rd party payer does or pays for.

The 3rd Party payer doesn't even know that a voucher was used, so it doesn't matter if the "stand for it"

 

[Anonymous]

What do they do, put hallucinogens in your coffee during an initial interview? How can this company look "pretty good" when their major product, Makena, is only reaching about 15% of the potential patients due to the unreasonable pricing of the product and the competition with compounded versions of the drug. Additionally, their newly re-introduced Gynazole-1 is not gaining favor with OB/Gyns, trending to achieve only about $1 million in annual revenue since remarketing began in January.
The company is a poorly managed circus. Have you noted that Divis, the CEO, has been awarded the dubious distinction of being voted the worst CEO two years in a row?

You see 15% I see 85% more to get. It do look good. So what kinda car can I get. Where is the trip I will win president club next year. Ive met many womens with years infections and they say that gynazole is easily the best and that makena is really going to grow by leaps and bounds this year and again. Plus my wife is a pharmacist who will switch for me.

 

[Anonymous]

The 3rd Party payer doesn't even know that a voucher was used, so it doesn't matter if the "stand for it"

You don't understand. After the patient co-pay, and any additional deduction is made for the voucher, the remainder of the cost is presented to the 3rd party payer for payment. If the payer does not list the product for reimbursement, then the patient has to pay the full price of the drug product, irregardless of KV's voucher. If the payer has a very high co-pay, the voucher may reduce what the patient has to pay, but ultimately, the payer has to pay any difference (if the payer lists the product for reimbursement.... most payers are NOT listing G-1 on their formulary for any payment)

 

[Anonymous]

You see 15% I see 85% more to get. It do look good. So what kinda car can I get. Where is the trip I will win president club next year. Ive met many womens with years infections and they say that gynazole is easily the best and that makena is really going to grow by leaps and bounds this year and again. Plus my wife is a pharmacist who will switch for me.

Maybe you should consider that most Rx's these days are paid for by 3rd party payers (governments and insurance companies). They decide what will be listed on their formularies for reimbursement, and what level co-pay is required. Your wife ain't going to do much switching if her pharmacy does not get paid for dispensing G-1.

 

[Anonymous]

You don't understand. After the patient co-pay, and any additional deduction is made for the voucher, the remainder of the cost is presented to the 3rd party payer for payment. If the payer does not list the product for reimbursement, then the patient has to pay the full price of the drug product, irregardless of KV's voucher. If the payer has a very high co-pay, the voucher may reduce what the patient has to pay, but ultimately, the payer has to pay any difference (if the payer lists the product for reimbursement.... most payers are NOT listing G-1 on their formulary for any payment)

Actually, you could not be more wrong...but you speak with such confidence I will let you go. Ask a pharmacist the order in which things happen and you will see how wrong you are.

 

[Anonymous]

Actually, you could not be more wrong...but you speak with such confidence I will let you go. Ask a pharmacist the order in which things happen and you will see how wrong you are.

If a drug product is not listed on a 3rd party payer's formulary for reimbursement, the patient pays full price for the product if the patient wants that product. That's a fact.

If a voucher is presented that subsidizes part of the co-pay of a formulary listed product, the 3rd party still has to pay the remainder of the approved cost of the product. That's a fact.

Most 3rd party payers are NOT listing Gynazole-1 in their formulary for reimbursement because the price is too high and other less expensive products are deemed effective.

 

[Anonymous]

You don't understand. After the patient co-pay, and any additional deduction is made for the voucher, the remainder of the cost is presented to the 3rd party payer for payment. If the payer does not list the product for reimbursement, then the patient has to pay the full price of the drug product, irregardless of KV's voucher. If the payer has a very high co-pay, the voucher may reduce what the patient has to pay, but ultimately, the payer has to pay any difference (if the payer lists the product for reimbursement.... most payers are NOT listing G-1 on their formulary for any payment)

Not sure i understand this argument, but G1 and Clindesse are all rebated Medicaid products, and neither are NYC blocked with any payer, so every voucher will work and the patient will never pay more than 30 bucks, and the manufacturer will eat the diff

 

[Anonymous]

Not sure i understand this argument, but G1 and Clindesse are all rebated Medicaid products, and neither are NYC blocked with any payer, so every voucher will work and the patient will never pay more than 30 bucks, and the manufacturer will eat the diff

Your are right regarding MEDICAID patients (indigent patients covered under the federal program administered by the states).

For patients covered under private Rx insurance (and some other groups) G-1 and Clindesses has to be listed in the groups formulary for reimbursement to occur without prior authorization. Even if listed, the products may be subject to a high co-pay. As it turns out today, most groups won't list G-1 or they require a very large co-pay ($30, $60, etc). What KV has planned to do to encourage the filling of G-1 Rx's, like they tried to do with Makena, is to offset the high co-pay with a voucher. For example, if the KV voucher is for $20 and the co-pay is $30 then the patient only has to pay $10.... however the 3rd party payer still has to pay the difference... KV does not eat the difference as with the Medicaid patient. The 3rd party payers don't like these voucher systems since they get stuck paying the difference.... usually what they do to offset the voucher is raise the co-pay very high. They did this with Makena with co-pays being as much as $120 and more, so that patient would have to pay at a level that they would refuse the branded Makena and choose the compounded version which had a small or no co-pay,

 

[Anonymous]

Your are right regarding MEDICAID patients (indigent patients covered under the federal program administered by the states).

For patients covered under private Rx insurance (and some other groups) G-1 and Clindesses has to be listed in the groups formulary for reimbursement to occur without prior authorization. Even if listed, the products may be subject to a high co-pay. As it turns out today, most groups won't list G-1 or they require a very large co-pay ($30, $60, etc). What KV has planned to do to encourage the filling of G-1 Rx's, like they tried to do with Makena, is to offset the high co-pay with a voucher. For example, if the KV voucher is for $20 and the co-pay is $30 then the patient only has to pay $10.... however the 3rd party payer still has to pay the difference... KV does not eat the difference as with the Medicaid patient. The 3rd party payers don't like these voucher systems since they get stuck paying the difference.... usually what they do to offset the voucher is raise the co-pay very high. They did this with Makena with co-pays being as much as $120 and more, so that patient would have to pay at a level that they would refuse the branded Makena and choose the compounded version which had a small or no co-pay,

You sure do know your stuff and certainly care a lot about our company? or maybe not?